MannKind Afrezza facing 'daunting' commercial hurdles, says JPMorgan JPMorgan believes Afrezza's label with a Black Box warning and requirement for pulmonary testing show the FDA's concerns around pulmonary toxicity. The firm believes the drug faces "daunting" commercial hurdles and it keeps a Neutral rating on the stock with a $6 price target.
News For MNKD From The Last 14 Days
Check below for free stories on MNKD the last two weeks.
Stocks with call strike movement; MNKD SUNE MannKind (MNKD) January 17 call option implied volatility increased 6% to 79, SunEdison (SUNE) October 28 call option implied volatility increased 3% to 58 according to IVolatility.